Bioavailability, Clinical Development, In-Vivo and Medicine

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioavailability

Clinical Development

In-Vivo

Medicine

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

MARCH 8, 2021

In addition to the ongoing clinical studies, Merck has conducted a comprehensive nonclinical program to characterize the safety profile of molnupiravir. This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo.

Trials

Trials In-Vivo Genotoxicity RNA

Strategies for Streamlining Small Molecule Formulation Development When Bridging from Candidate Selection to First-in-Human Clinical Testing

Pharmaceutical Technology

FEBRUARY 13, 2023

The continued high level of interest in small molecules presents multiple opportunities to select a candidate that is ‘developable’, with subsequent rapid progression toward first-in-human (FIH) clinical testing. We start by using in-silico modeling of any pre-existing data associated with the lead compounds.

Development

Development In-Vivo Clinical Trials Clinical Trials

Clinical Research Informer

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Strategies for Streamlining Small Molecule Formulation Development When Bridging from Candidate Selection to First-in-Human Clinical Testing

Stay Connected